IL17A and neoplasm: Chen et al., through immunohistochemical testing and analysis of 192 patients with gastric adenocarcinoma, reported that low expression of IL-17 in tumor tissues is an independent predictor of poor prognosis, with patients expressing higher levels of IL-17 demonstrating significantly better five-year overall survival rates than those with lower levels of IL-17 (14).